AIThe Next Webabout 1 hour ago
AI lung drug lowers biological age markers in trial
1 min read
Insilico Medicine's AI-designed lung drug rentosertib lowered biological age markers in a 42-patient analysis published in Nature Biotechnology. Six independent proteomic clocks showed treated patients appeared 2.7 to 3.5 years younger at week four. The phase 2a trial's primary endpoint was safety, and rentosertib entered phase 3 in July.
Level
Hype check
Tap to vote and see what everyone thinks.
